Skip to main content
. 2009 Nov;1(3):183–205. doi: 10.1177/1758834009349119

Table 2.

Randomized phase III trial of sorafenib compared to placebo for renal cell cancer patients progressing on prior, predominantly cytokine, therapy [Escudier et al. 2009a, 2007b].

Treatment PFS p value OS p value
Sorafenib 5.5 <0.0001 17.8 0.029
Placebo 2.8 14.3

OS, overall survival; PFS, progression-free survival.